Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455975 · ClinicalTrials.gov registry record · Phase 2
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
A Phase 2 study of Kidney Cancer and Renal Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
- 13
- Study locations
NCT00455975 is a Phase 2 study of Kidney Cancer and Renal Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 119 participants, below the 878-participant average among 60 other Kidney Cancer trials with a reported enrollment target (86% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT00455975, a Phase 2 study of Kidney Cancer and Renal Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
- 13
- Study locations
Study Summary
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
Conditions Studied
Interventions
- DRUG Bevacizumab
Study Locations (13)
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Family Cancer Center - Collierville
- Tennessee Oncology, PLLC - Nashville
Florida
- Florida Cancer Specialists - Fort Myers
Georgia
- Northeast Georgia Medical Center - Gainesville
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Maryland
- Center for Cancer and Blood Disorders - Bethesda
Nebraska
- Methodist Cancer Center - Omaha
North Carolina
- Cancer Care of Western North Carolina - Asheville
Ohio
- Oncology Hematology Care - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455975
The ClinicalTrials.gov registry entry for NCT00455975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 878-participant average among 60 other Kidney Cancer trials with a reported enrollment target (86% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00455975 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Tennessee, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00455975 about?
NCT00455975 is a clinical study titled "High-dose Bevacizumab in Advanced Renal Carcinoma Patients". This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
What is the current status of trial NCT00455975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2007-02. Estimated completion is 2013-09.
What conditions does trial NCT00455975 study?
This clinical trial studies the following conditions: Kidney Cancer, Renal Cancer.
What interventions are being tested in trial NCT00455975?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00455975?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00455975 being conducted?
This trial has 13 study locations across Florida, Georgia, Kentucky, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.